Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 1:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 1,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Disorder Clear all

Conditions: Retinitis Pigmentosa 11, Retinal Degeneration, Retinal Disease, Eye Diseases Hereditary, Retinal Dystrophies
Interventions: VP-001; Drug
Lead sponsor: PYC Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Jacksonville, Florida • Miami, Florida • Ann Arbor, Michigan + 3 more

Conditions: Age-Related Macular Degeneration
Interventions: Photodynamic Therapy (PDT) with Visudyne (verteporfin), Macugen (pegaptanib sodium); Drug
Lead sponsor: Eyetech Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Primary Open Angle Glaucoma
Interventions: dietary supplement with antioxidants, Placebo; Dietary Supplement
Lead sponsor: ScienceBased Health; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hemianopia, Hemianopsia, Peripheral Visual Field Defect, Blindness, Retinitis Pigmentosa, Glaucoma
Interventions: Collision warning device; Device
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Retinal Detachment, Diabetic Retinopathy
Interventions: Avastin (bevacizumab), Sham injection; Drug · Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Age-related Macular Degeneration (AMD)
Interventions: Lutein-enriched-egg beverage (NWT-02), Placebo; Dietary Supplement
Lead sponsor: Newtricious R&D BV; Industry
Eligibility: 50 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neovascular Age-related Macular Degeneration, Retinal Disease, Retinal Degeneration, Macular Degeneration
Interventions: GEM103, Aflibercept, Sham; Biological · Drug
Lead sponsor: Gemini Therapeutics, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 23
States / cities: Phoenix, Arizona • Campbell, California • Encino, California + 19 more

Conditions: Retinopathy, Diabetic
Interventions: Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]; Drug
Lead sponsor: Ophthalmic Consultants of the Capital Region; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Troy, New York

Conditions: Inherited Retinal Degeneration Associated With RPGR Mutations, Inherited Retinal Degeneration Associated With Biallelic RPE65 Mutations
Interventions: Not listed
Lead sponsor: University College, London; Other
Eligibility: Up to 50 Years
Enrollment: 4,887 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Incomplete Spinal Cord Injury, Spasticity, Muscle
Interventions: Motor Skill Training (MST), Transcutaneous Spinal Stimulation (TSS); Behavioral · Device
Lead sponsor: Shepherd Center, Atlanta GA; Other
Eligibility: 18 Years to 70 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Diabetic Macular Edema
Interventions: Sirolimus, Placebo; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Stargardt's Macular Dystrophy
Interventions: MA09-hRPE; Biological
Lead sponsor: Astellas Institute for Regenerative Medicine; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 3
States / cities: Los Angeles, California • Miami, Florida • Philadelphia, Pennsylvania

Conditions: Age-related Macular Degeneration, Subfoveal Choroidal Neovascularization, Subretinal Scarring, Subretinal Fibrosis
Interventions: RXI-109; Drug
Lead sponsor: RXi Pharmaceuticals, Corp.; Industry
Eligibility: 50 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Retinopathy of Prematurity
Interventions: Not listed
Lead sponsor: Pediatrix; Other
Eligibility: Up to 7 Days
Enrollment: 324 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2020
U.S. locations: 2
States / cities: South Bend, Indiana • Las Vegas, Nevada

Conditions: Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma, Hepatoblastoma, Wilms Tumor, Rhabdoid Tumor, Carcinoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma, Clear Cell Sarcoma, Malignant Peripheral Nerve Sheath Tumors, Desmoplastic Small Round Cell Tumor, Soft Tissue Sarcoma, Neuroblastoma, Melanoma
Interventions: second generation 4-1BBζ B7H3-EGFRt-DHFR, second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG, Pembrolizumab; Biological · Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 0 Years to 26 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2040
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Age-Related Macular Degeneration
Interventions: Minocycline; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 55 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Proliferative Diabetic Retinopathy
Interventions: Prompt Panretinal Photocoagulation, 0.5-mg Ranibizumab, Deferred panretinal photocoagulation; Other · Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 48
States / cities: Phoenix, Arizona • Loma Linda, California • Palm Springs, California + 42 more

Conditions: Anemia of Prematurity
Interventions: Red blood cell transfusion; Procedure
Lead sponsor: McMaster University; Other
Eligibility: Up to 48 Hours
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 2
States / cities: Albany, New York • Brooklyn, New York

Conditions: Retinal Vein Occlusion, Posterior Vitreous Detachment
Interventions: Ranibizumab; Drug
Lead sponsor: Barnes Retina Institute; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Retinal Diseases, Fuchs Endothelial Dystrophy, Macular Hole, Epiretinal Membrane, Retinal Detachment
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 2,911 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: ROP Threshold
Interventions: Not listed
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 30 Weeks to 40 Weeks
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 2
States / cities: Houston, Texas • Lubbock, Texas

Conditions: Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma
Interventions: filgrastim, carboplatin, etoposide, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: Up to 18 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 3
States / cities: St Louis, Missouri • Buffalo, New York • Houston, Texas

Conditions: Severe Diabetic Retinopathy, Central Retinal Vein Occlusion, Chronic Inflammation, Infectious Diseases
Interventions: anecortave acetate; Drug
Lead sponsor: Manhattan Eye, Ear & Throat Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Age-Related Macular Degeneration
Interventions: Avastin, Photodynamic Therapy (PDT), Preservative-Free Triamcinolone Acetonide (TAC-PF); Drug · Procedure
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 50 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 11
States / cities: Fort Lauderdale, Florida • Orlando, Florida • Pensacola, Florida + 8 more

Search by objective public record fields.

A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001

Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)

The Effects of an Antioxidant Formulation on Ocular Blood Flow

Collision Warning Device for Blind and Visually Impaired

Avastin for PDR (Proliferative Diabetic Retinopathy)

Intervention Trial in Early Age-related Macular Degeneration

A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration

DEXTENZA VS. PREDNISOLONE ACETATE 1% Macular Edema With Diabetic Retinopathy After Cataract Surgery

Monitoring and Early Detection of Treatable Inherited RETinal Disease in Children and Adolescents

Activating Spinal Circuits to Improve Walking, Balance, Strength, and Reduce Spasticity

Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients

Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD

Registry for Severe ROP and Treatment on Visual Outcomes

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration

Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

Premature Infants in Need of Transfusion (PINT)

Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations

DISCOVER Study: Microscope-integrated Intraoperative OCT Study

39946-I Laser and Bevacizumab Treatment for Retinopathy of Prematurity

Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer

Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).

TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration